UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000001007
Receipt number R000001213
Scientific Title The additive effects of Pranlukast in stable asthmatic patients with the regular use of FP/LABA combination drug (2) Open-label, randomized, and cross-over study
Date of disclosure of the study information 2008/02/04
Last modified on 2010/03/19 02:27:16

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The additive effects of Pranlukast in stable asthmatic patients with the regular use of FP/LABA combination drug
(2) Open-label, randomized, and cross-over study

Acronym

The additive effects of Pranlukast in stable asthmatic patients with the regular use of FP/LABA combination drug
(2) Open-label, randomized, and cross-over study

Scientific Title

The additive effects of Pranlukast in stable asthmatic patients with the regular use of FP/LABA combination drug
(2) Open-label, randomized, and cross-over study

Scientific Title:Acronym

The additive effects of Pranlukast in stable asthmatic patients with the regular use of FP/LABA combination drug
(2) Open-label, randomized, and cross-over study

Region

Japan


Condition

Condition

Asthma

Classification by specialty

Pneumology Clinical immunology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the inhibitory effects of a LT receptor antagonist, Pranlukast on peripheral airway inflammation in stable asthmatic patients who use FP/LABA combination drug regularly and are well-controlled or better based on self-evaluation.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Phase IV


Assessment

Primary outcomes

Peripheral airway inflammation in induced sputum (Eosinophils, ECP and Eotaxin)

Key secondary outcomes

1.Asthmatic symptoms and QOL(AQLQ)
2.Pulmonary functions (PEF, FEV1, FEF50, FEF75)
3.Eosinophils in peripheral blood


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation

NO

Institution consideration


Blocking


Concealment

Numbered container method


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

The first 4 weeks are treated with FP/LABA combination drug and Pranlukast.
The second 4 weeks are treated with only FP/LABA combination drug.

Interventions/Control_2

The first 4 weeks are treated with only FP/LABA combination drug.
The second 4 weeks are treated with. FP/LABA combination drug and Pranlukast.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

16 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1.Patients with FP/LABA combination drug more than 3 months.
2.Stable asthmatic patients who evaluate themselves to be well-controlled or better.

Key exclusion criteria

1.Past treatments with anti-LT drugs in the previous 3 months.
2.Past treatments with oral corticosteroids in the previous 2 weeks.
3.Chronic obstructive lung disease(COPD) and other respitatory disease.
4.Severe liver, kidney, heart , hematic and other diseases
5.Inappropriate patients from the doctor's viewpoint.

Target sample size

50


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Mitsuru Adachi

Organization

Showa University School of Medicine

Division name

First Department of Internal Medicine

Zip code


Address

1-5-8, Hatanodai, Sinagawa-ku, Tokyo

TEL

03-3784-8000

Email



Public contact

Name of contact person

1st name
Middle name
Last name Hiroyuki Ohbayashi

Organization

JA Tohno Kousei Hospital

Division name

Allergy and Respiratory Medicine

Zip code


Address

76-1, Toki-Cho, Mizunami City, Gifu Pref., 509-6101, Japan

TEL

0572-68-4111

Homepage URL


Email

ohbayasi@nn.iij4u.or.jp


Sponsor or person

Institute

JA Tohno Kousei Hospital

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2008 Year 02 Month 04 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2007 Year 12 Month 18 Day

Date of IRB


Anticipated trial start date

2008 Year 03 Month 01 Day

Last follow-up date

2009 Year 03 Month 01 Day

Date of closure to data entry

2009 Year 03 Month 01 Day

Date trial data considered complete

2009 Year 03 Month 01 Day

Date analysis concluded

2009 Year 04 Month 01 Day


Other

Other related information



Management information

Registered date

2008 Year 02 Month 01 Day

Last modified on

2010 Year 03 Month 19 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001213


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name